Brief: Pherecydes Pharma: Positive Preclinical Results For Inhaled Phage Therapy
27/06/2022 06:08
June 27 (Reuters) - Pherecydes Pharma SA ALPHE.PA :
* POSITIVE PRECLINICAL RESULTS FOR INHALED PHAGE THERAPY
PRESENTED
TO THE REANIMATION 2022 CONFERENCE
* PRECLINICAL STUDY DEMONSTRATES BENEFITS OF INHALED
PHERECYDES
PHARMA PHAGES IN TREATING VENTILATOR-ASSOCIATED PNEUMONIA
* STUDY WAS CARRIED OUT WITHIN FRAMEWORK OF PNEUMOPHAGE
PROJECT,
ASSOCIATING UMR1100 AND DIFFUSION TECHNIQUE FRANÇAISE COMPANY,
AIMED AT DEMONSTRATING EFFECTIVENESS OF INHALED PHAGE THERAPY IN
TREATING VENTILATOR-ASSOCIATED INFECTIONS
* WORK UNDERTAKEN SHOWED THAT USE OF PHERECYDES PHARMA'S
ANTI-P.
AERUGINOSA PHAGES SIGNIFICANTLY REDUCED LUNG BACTERIAL LOAD
(1.5-LOG REDUCTION, P < 0.001)
Source text for Eikon: ID:nBw5xBNB2a
Further company coverage: ALPHE.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Pherecydes Pharma SA
See all newsBrief: Erytech And Pherecydes Announce Merger And Name Change To Phaxiam Therapeutics
Brief: Pherecydes Pharma SA - Pherecydes Pharma And Erytech Pharma Shareholders Approve Merger Between Two Companies To Create Phaxiam Therapeutics
Brief: Erytech Announces That The Commercial Court Has Rejected Akkadian's Request To Postpone The Vote On The Merger With Pherecydes Pharma
Brief: Erytech: urges shareholders to vote for merger with Pherecydes and dismisses Akkadian's moves
Brief: Erytech Pharma Says Akkadian Has Initiated Proceedings To Postpone Vote On Merger With Pherecydes